Listed

ENDRA Life Sciences Inc.: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 14, 2017 and accepted by EDGAR at Nov 14, 2017, 16:20 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Gross profit3 months2017-07-01 to 2017-09-30$168.7kus-gaap:GrossProfit
Gross profit9 months2017-01-01 to 2017-09-30$175.1kus-gaap:GrossProfit
Research and development3 months2017-07-01 to 2017-09-30$300.5kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$571.1kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$910.9kus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$2.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-07-01 to 2017-09-30$2.0kus-gaap:InterestExpense
Interest expense9 months2017-01-01 to 2017-09-30$752.8kus-gaap:InterestExpense
Income tax3 months2017-07-01 to 2017-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2017-01-01 to 2017-09-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2017-07-01 to 2017-09-30−$908.9kus-gaap:NetIncomeLoss
Net income9 months2017-01-01 to 2017-09-30−$3.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-07-01 to 2017-09-30−$0.23us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2017-01-01 to 2017-09-30−$1.30us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2017-01-01 to 2017-09-30−$1.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2017-01-01 to 2017-09-30$7.9kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-09-30$7.0mus-gaap:Cash
Current assetsAt period end2017-09-30$7.2mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$7.5mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$312.0kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$312.0kus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$7.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001654954-17-010633. Last ingested by Listed: Nov 10, 2026, 17:03 ET. Listed shows no prices and gives no investment advice.